EUVIMEDEUVIMED entdecken
VergleichsstudiePragmatische StudieRandomisierte kontrollierte StudieOpen Access

Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen

Yi-Chia Lee, Jui-Hsuan Liu, Duco T Mülder, Jeong Yun Yang, Tsung-Hsien Chiang, Wen-Feng Hsu, Han-Mo Chiu, Wei-Wen Su, Kun-Ching Chou, Sam Li-Sheng Chen, Jean Ching-Yuan Fann, Sherry Yueh-Hsia Chiu und 14 weitere

JAMA · 07.07.2026 · 336 (1) · 35

DOI: 10.1001/jama.2026.6908 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA, erschienen am 07.07.2026. Verfasst von Yi-Chia Lee und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan. Hauptthemen laut MEDLINE: Antigens, Bacterial, Colorectal Neoplasms, Feces, Helicobacter Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Helicobacter pylori infection is the leading cause of gastric cancer, yet the economic value of population-based screening and eradication remains uncertain.

Objective

To project the lifetime health benefits and costs of invitation to 1-time H pylori stool antigen testing added to biennial fecal immunochemical test (FIT) screening compared with FIT alone. Design, Setting, and Participants Lifetime cost-effectiveness analysis conducted using a Markov decision-analytic model to simulate a cohort informed by a pragmatic randomized clinical trial in Changhua County, Taiwan. The model adopted a 30-year time horizon and projected long-term outcomes, including gastric and colorectal cancer mortality, quality-adjusted life-years (QALYs; incorporating both life expectancy and health-related quality of life), and health care expenditures. Costs were evaluated from a societal perspective. One-way and probabilistic sensitivity analyses were performed. Future costs and QALYs were discounted at an annual rate of 3%. Exposures Helicobacter pylori stool antigen testing plus FIT or FIT alone. Main Outcomes and Measures Incremental cost-effectiveness ratio of invitation for H pylori stool antigen testing plus FIT vs FIT alone, measured as the additional cost required to gain 1 QALY per person. Secondary outcomes included net monetary benefit and benefit-cost ratio.

Results

Compared with FIT alone, invitation to co-testing was more effective and less expensive (dominant), with a base-case cost-saving incremental cost-effectiveness ratio of $2094 per QALY gained (95% CI, $12 359 saved to $7291 additional cost). This resulted in a positive net monetary benefit, indicating that health benefits exceeded costs, and a benefit-cost ratio of 5.08, indicating an approximately 5-fold return on investment in the Taiwanese population. At a willingness-to-pay threshold of 1 × the Taiwan gross domestic product per QALY ($33 365), invitation to co-testing remained cost-saving in 65.7% of simulations. From a US cost perspective, invitation to co-testing was not cost-saving but remained cost-effective at the trial base-case H pylori prevalence. Sensitivity analyses identified H pylori prevalence as the dominant driver; co-testing exceeded a $100 000-per-QALY threshold when prevalence fell below 21.9%. Conclusions and Relevance In a pragmatic real-world setting with incomplete adherence, invitation to combined H pylori stool antigen testing and FIT was more cost-effective than FIT alone, improving lifetime outcomes and yielding cost savings in Taiwan while remaining cost-effective in higher-cost settings under moderate H pylori prevalence. Trial Registration ClinicalTrials.gov Identifier: NCT01741363

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, BacterialColorectal NeoplasmsFecesHelicobacter InfectionsHelicobacter pyloriMass ScreeningStomach NeoplasmsAgedFemaleHumansMaleMiddle AgedCost-Effectiveness AnalysisMarkov ChainsOccult BloodQuality-Adjusted Life YearsTaiwanImmunochemistryPrevalenceAged, 80 and over

Substanzen

Antigens, Bacterial

Autor:innen und Institutionen

  • Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan.
  • Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan.
  • Department of Medical Research, National Taiwan University Hospital, Taipei City, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
  • Lienchiang County Hospital, Nangan Township, Lienchiang County, Matsu Islands, Taiwan.

Zitieren

APA

Lee, Y. C., Liu, J. H., Mülder, D. T., Yang, J. Y., Chiang, T. H., Hsu, W. F., Chiu, H. M., Su, W. W., Chou, K. C., Chen, S. L., Fann, J. C., Chiu, S. Y., Chuang, S. L., Chen, Y. R., Chu, T. C., Chang, M. Y., Chen, S. T., Hu, T. H., Fang, Y. J., …, & Collaborators of the Taiwan Community-Based Integrated Screening Group (2026). Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen. JAMA, 336(1), 35. https://doi.org/10.1001/jama.2026.6908

Vancouver

Lee YC, Liu JH, Mülder DT, Yang JY, Chiang TH, Hsu WF, et al. Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen. JAMA. 2026;336(1):35. doi:10.1001/jama.2026.6908

BibTeX
@article{Lee2026,
  author = {Lee, Yi-Chia and Liu, Jui-Hsuan and Mülder, Duco T and Yang, Jeong Yun and Chiang, Tsung-Hsien and Hsu, Wen-Feng and Chiu, Han-Mo and Su, Wei-Wen and Chou, Kun-Ching and Chen, Sam Li-Sheng and Fann, Jean Ching-Yuan and Chiu, Sherry Yueh-Hsia and Chuang, Shu-Lin and Chen, Yi-Ru and Chu, Teresa Cheng-Chieh and Chang, Monal Yu-Hsuan and Chen, Shih-Tien and Hu, Tsung-Hui and Fang, Yi-Jen and Liou, Jyh-Ming and Wu, Ming-Shiang and Yeh, Yen-Po and Hur, Chin and Yen, Amy Ming-Fang and Chen, Tony Hsiu-Hsi and Collaborators of the Taiwan Community-Based Integrated Screening Group, Collaborators of the Taiwan Community-Based Integrated Screening Group},
  title = {Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen},
  journal = {JAMA},
  year = {2026},
  volume = {336},
  number = {1},
  pages = {35},
  doi = {10.1001/jama.2026.6908}
}
Kostenlos starten →